IBRX - Company ID 0001326110
The table below shows ImmunityBio, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$75.36M | -$85.91M | -$106.98M | -$84.31M | -$74.93M | -$60.47M |
| Capital expenditure | $1.78M | $1.12M | $1.26M | $8.43M | $27.35M | $7.08M |
| Investing cash flow | -$31.65M | $4.13M | -$35.62M | -$8.48M | -$69.31M | $31.84M |
| Dividends paid | - | - | - |
ImmunityBio, Inc. reported operating cash flow of -$304.94M for fiscal year 2025. That is up 22.1% from -$391.24M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$38.59M (FY 2016) to -$304.94M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $223.93M | -$982.00K | $10.22M | $76.89M | -$298.00K | $38.50M |